Literature DB >> 12702049

Enhanced intestinal inflammation induced by dextran sulfate sodium in tumor necrosis factor-alpha deficient mice.

Yuji Naito1, Tomohisa Takagi, Osamu Handa, Takeshi Ishikawa, Shuji Nakagawa, Taiji Yamaguchi, Norimasa Yoshida, Masato Minami, Masakazu Kita, Jiro Imanishi, Toshikazu Yoshikawa.   

Abstract

BACKGROUND AND AIMS: Tumor necrosis factor-alpha (TNF-alpha) is a potent pro-inflammatory cytokine thought to be involved in the pathogenesis of inflammatory bowel disease. To further define the role of TNF-alpha in intestinal inflammation, we studied the effects of dextran sulfate sodium (DSS) administration in mice with targeted deletions of TNF-alpha gene.
METHODS: Acute colitis was induced in female TNF-alpha-/- and TNF-alpha+/+ mice by administering 4.5% DSS orally in drinking water for seven days. The colonic mucosal injury and inflammation was evaluated based on body weight changes, total colon length, luminal hemoglobin, and histological findings. Colonic mRNA expression for inducible nitric oxide synthase (iNOS), TNF-alpha, interferon-gamma (IFN-gamma) and interleukin-4 (IL-4) were measured by reverse transcription polymerase chain reaction (RT-PCR), and nuclear factor kappaB (NF-kappaB) activation was evaluated by electrophoretic mobility shift assay.
RESULTS: In each assessment, colonic injury was significantly aggravated in DSS-treated TNF-alpha-/- mice compared with DSS-treated TNF-alpha+/+ mice. The survival rate of TNF-alpha-/- mice on day seven was 40%; in contrast, all TNF-alpha+/+ mice were alive. Histological study also showed an enhanced infiltration of inflammatory cells, especially neutrophils, and mucosal cell disruption in DSS-treated TNF-alpha-/- mice compared with DSS-treated TNF-alpha+/+ mice. On day seven, mRNA levels of IFN-gamma and IL-4 in the colons of TNF-alpha-/- mice were faint or not detected; in contrast, those of TNF-alpha+/+ mice were detected. Although the expression of iNOS mRNA and luminal nitrite levels were similarly increased in both mice on day seven, this induction was delayed in TNF-alpha-/- mice during the early phase. The degree of NF-kappaB binding activity seemed to be similar between the two types of mice on day seven.
CONCLUSION: DSS-induced inflammation is significantly enhanced in TNF-alpha-/- mice compared to TNF-alpha+/+ mice. These data suggest that persistent and marked blockage of TNF-alpha bioactivity may provide a detrimental effect on acute intestinal inflammation. Copyright 2003 Blackwell Publishing Asia Pty Ltd

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12702049     DOI: 10.1046/j.1440-1746.2003.03034.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  59 in total

1.  The role of Gr-1(+) cells and tumour necrosis factor-α signalling during Clostridium difficile colitis in mice.

Authors:  Andrew J McDermott; Kathryn E Higdon; Ryan Muraglia; John R Erb-Downward; Nicole R Falkowski; Roderick A McDonald; Vincent B Young; Gary B Huffnagle
Journal:  Immunology       Date:  2015-04       Impact factor: 7.397

2.  The specific JNK inhibitor SP600125 targets tumour necrosis factor-alpha production and epithelial cell apoptosis in acute murine colitis.

Authors:  Kiran Assi; Rex Pillai; Antonio Gómez-Muñoz; David Owen; Baljinder Salh
Journal:  Immunology       Date:  2006-05       Impact factor: 7.397

3.  Functionally enhanced siRNA targeting TNFα attenuates DSS-induced colitis and TLR-mediated immunostimulation in mice.

Authors:  Sandra M Ocampo; Carolina Romero; Anna Aviñó; Joan Burgueño; Miguel A Gassull; Jordi Bermúdez; Ramon Eritja; Ester Fernandez; Jose C Perales
Journal:  Mol Ther       Date:  2011-11-01       Impact factor: 11.454

4.  Paradoxical effects of constitutive human IL-32{gamma} in transgenic mice during experimental colitis.

Authors:  Jida Choi; Suyoung Bae; Jaewoo Hong; Soyoon Ryoo; Hyunjhung Jhun; Kwangwon Hong; Doyoung Yoon; Siyoung Lee; Erk Her; Wonhyuk Choi; Jeonghwan Kim; Tania Azam; Charles A Dinarello; Soohyun Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-15       Impact factor: 11.205

5.  Genetic deletion of Klf4 in the mouse intestinal epithelium ameliorates dextran sodium sulfate-induced colitis by modulating the NF-κB pathway inflammatory response.

Authors:  Amr M Ghaleb; Hamed Laroui; Didier Merlin; Vincent W Yang
Journal:  Inflamm Bowel Dis       Date:  2014-05       Impact factor: 5.325

Review 6.  Extra-adrenal glucocorticoid synthesis in the intestinal epithelium: more than a drop in the ocean?

Authors:  Mario Noti; Daniel Sidler; Thomas Brunner
Journal:  Semin Immunopathol       Date:  2009-06-03       Impact factor: 9.623

7.  Probiotics promote gut health through stimulation of epithelial innate immunity.

Authors:  Cristiano Pagnini; Rubina Saeed; Giorgos Bamias; Kristen O Arseneau; Theresa T Pizarro; Fabio Cominelli
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-14       Impact factor: 11.205

8.  Inflammation-induced JMJD2D promotes colitis recovery and colon tumorigenesis by activating Hedgehog signaling.

Authors:  Minghui Zhuo; Wenbo Chen; Shaohui Shang; Peng Guo; Kesong Peng; Ming Li; Pingli Mo; Yongyou Zhang; Xingfeng Qiu; Wengang Li; Chundong Yu
Journal:  Oncogene       Date:  2020-02-24       Impact factor: 9.867

9.  Interleukin-19 contributes as a protective factor in experimental Th2-mediated colitis.

Authors:  Yasuyuki Fujimoto; Yasu-Taka Azuma; Yukiko Matsuo; Mitsuru Kuwamura; Nobuyuki Kuramoto; Mariko Miki; Naoki Azuma; Midori Teramoto; Kazuhiro Nishiyama; Takeshi Izawa; Hidemitsu Nakajima; Tadayoshi Takeuchi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-12-09       Impact factor: 3.000

10.  Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease.

Authors:  Andrew M Smith; Farooq Z Rahman; Bu'Hussain Hayee; Simon J Graham; Daniel J B Marks; Gavin W Sewell; Christine D Palmer; Jonathan Wilde; Brian M J Foxwell; Israel S Gloger; Trevor Sweeting; Mark Marsh; Ann P Walker; Stuart L Bloom; Anthony W Segal
Journal:  J Exp Med       Date:  2009-08-03       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.